When AST was 13, almost all people in the board happy and said how good it was and hope it go to 20, 30 .
Now just look at it, about $6.
stock has its intrinsic value. that could not change dramatically. Biotech company generally spent 15 years to take one product from RD to the market， even assay kits may quick but still have long way to go. Investors don't have that that kind of patient to wait. believe or not, TROV will be forgot in weeks.
Even the urine gene assay is in good association with cancer , no any Doctor can make the cancer diagnosis just depending on this kind of urine assay result.
A cancer final diagnosis still need biopsy and pathology exam before any other test. that is not replaceable.
So, such a assay won't help or benefit to patient.
This kind of stock can not hold at this level after going up for several folds.
TROV technology don't have much advantage,
Anyway, their product is only diagnosis reagent, its market and profit are very limited.
All people have the tumor growth potential. TROV's scanning test don't make much sense. Even the positive result still can not confirm the tumor and tell the tumor location, size and malignant or not.
It become a new big bubble.
It means it cash almost born out now for second Q, Am I right? They have to issue more shares or get loan?
Its balance sheet looks ugly and run out of cash.
Any biotech stock has big potential loss before drug going into market, RCPT is long way from it.
Mark my word: This stock pump up without any solid news or FA support. it was just the manipulation.
Cancer treatment data is so great for a small company with 50 millions of CAP.
You can find a lot biotech stocks with several Billions CAP without any drug to market.
ICPT RCPT JUNO KITE etc